FDA Authorizes Updated mRNA COVID-19 Vaccines Targeting KP.2 Variant for 2024-2025 Season

FDA Authorizes Updated Monovalent COVID-19 Vaccines Targeting KP.2 for 2024-2025 Season

The FDA authorized three updated monovalent COVID-19 vaccines on August 22, 2024. The new formulations from Moderna, Pfizer-BioNTech and Novavax target the KP.2 strain of the JN.1 lineage of SARS-CoV-2. This replaces prior vaccines based on the XBB.1.5 variant. The decision aligns with earlier WHO recommendations on strain selection and with CDC guidance for the fall respiratory virus season. [1][2][3]

The FDA based its decision on immunogenicity data that compared the updated shots to prior versions. This approach mirrors the annual process used for influenza vaccines. The World Health Organization had earlier advised a shift to the JN.1 lineage in April 2024. [3]

Targeted Variant

The vaccines focus on the KP.2 strain within the JN.1 lineage. That lineage now accounts for a growing share of circulating SARS-CoV-2 viruses. FDA documents note that the update should restore protection that had begun to wane against newer variants. [1][3]

Manufacturers and Formulations

Three products received authorization. Moderna’s Spikevax and Pfizer-BioNTech’s Comirnaty use updated mRNA technology. Novavax supplies a protein-based adjuvanted vaccine. All three are monovalent, meaning they contain antigen from a single strain. [1]

CDC Alignment

CDC guidance issued after the FDA action recommends the updated vaccines for everyone 6 months of age and older. The agency’s stay-up-to-date page reflects the same 2024-2025 composition and age range. This creates a unified federal stance ahead of the fall and winter respiratory virus season. [2]

Evidence Basis

Regulators relied on bridging studies that measured antibody responses rather than new clinical efficacy trials focused solely on KP.2. Earlier formulations had established safety records. The updated versions showed comparable profiles in lab and early human data. Post-market surveillance systems will track real-world performance. [1]

What this means

The authorization sets the exact antigen composition that will be manufactured and distributed for the 2024-2025 season. It replaces the XBB.1.5-based vaccines. Protection against currently dominant lineages is expected to improve compared with prior formulations. The extent of that improvement will depend on how closely circulating strains continue to match KP.2. Availability will follow usual fall distribution patterns.

Key takeaways

• The FDA issued the authorizations on August 22, 2024 for vaccines aimed at the KP.2 strain of the JN.1 lineage. [1]
• Moderna, Pfizer-BioNTech and Novavax each received clearance for one updated monovalent product. [1]
• CDC recommendations cover all individuals 6 months of age and older and match the FDA’s authorized population. [2]
• Strain selection drew from WHO guidance issued in April 2024 that favored the JN.1 lineage. [3]
• Safety and immune response data come from bridging studies linked to previously authorized formulations. [1]

Limitations

Authorization relies on immunogenicity bridging studies rather than new large-scale efficacy trials for the exact KP.2 formulation. Real-world effectiveness and duration of protection against infection and severe disease will only be known after rollout and ongoing surveillance. Vaccine uptake, strain evolution, and emerging variants may alter public health impact. Rare adverse events continue to require monitoring via VAERS and other systems.

FAQ

Which specific SARS-CoV-2 variant do the 2024-2025 vaccines target?
The vaccines target the KP.2 strain of the JN.1 lineage. [1][3]

What manufacturers and vaccine types received FDA authorization?
Moderna (mRNA Spikevax), Pfizer-BioNTech (mRNA Comirnaty) and Novavax (protein-based adjuvanted) all received authorization for monovalent formulations. [1]

How do CDC recommendations align with the FDA authorization?
The CDC states that everyone 6 months and older should receive an updated vaccine, directly reflecting the FDA’s authorized age range and strain composition. [2]

What is the evidence basis for authorizing the updated formulations?
The FDA reviewed immunogenicity bridging data that linked the new KP.2 versions to earlier vaccines with established safety records. [1]